Gluetacs Therapeutics, the 1^st biotech company incubated by ShanghaiTech University, is a biotech company focusing on the research and development of small molecule oral protein degrader, established in February 2020, formally started to operate in March 2021, and led by a number of scientists who have been working in the field of protein degradation for many years.

Our company owns independent intellectual property of molecular glue degrader (GLUE) and bifunctional degrader (GLUETAC) development platform, and has filed and granted over a hundred patents in this field across different countries, with unique and differentiated technology routes and development strategies. Our company has independently established artificial intelligence virtual screening platform, in vitro drug screening platform, pharmacokinetic platform, proteomics platform and in vivo efficacy testing platform, realizing the complete construction of the whole process of drug research and development system.

Since its official operation in March 2021, Gluetacs has successfully promoted two drug candidates into clinical trials, having fully validated and demonstrated the ability of GlueTacs^® platform to rapidly discover drug candidates and advance pipelines. Our company has also become a training base of innovative master degree and doctor of engineering of ShanghaiTech University, and has been cooperating with more than ten academics and professors at home and abroad in terms of scientific research.

In accordance with the concepts for development ‘innovation, pioneering, and benefiting patients’, Gluetacs has laid out a series of differentiated product pipelines based on unmet medical needs and disease-relevant pathways. The R&D team maintains its enthusiasm to accelerate the speed of drug research and development to benefit the patients as soon as possible and contribute to the society.